IL-33 human

IL-33 (interleukin 33) is a potent immunomodulatory cytokine that belongs to the IL-1 family, which also includes IL-1β and IL-18. This protein as first identified as a nuclear factor showing predominant expression in human high endothelial venules. IL-33 shows high expression levels in endothelial cells and epithelium, such as keratinocytes, that are in direct contact with the environment.
Recombinant human IL-33 produced from Escherichia coli is a non-disulfide-linked homodimeric, non-glycosylated polypeptide chain consisting of 160 amino acids and having a total molecular mass of 18.1kDa.

IL-33 (interleukin 33) functions as an extracellular cytokine, and also translocates to the nucleus where it inhibits gene expression. It acts as a ligand for ST2/ IL-1 receptor-like 1 (growth STimulation expressed gene 2), and ST2 is expressed on cells such as CD34⁺ hematopoietic progenitor cells, eosinophils, basophils, T-helper 2 cell (Th2), and dendritic, NK (natural killer), endothelial and mast cells. Polymorphisms in this gene as well as its receptor are linked with atopic dermatitis, allergies and asthma. This protein is also thought to function as a profibrogenic cytokine, signaling through ST2, where it facilitates the stimulation and progression of fibrosis in different types of organs and tissues, such as pulmonary, liver, and uterine leiomyoma. In renal transplant recipients, the increased levels of IL-33 might be implicated in the pathogenesis of chronic allograft dysfunction (CAD).

Sterile filtered and lyophilized with 10 mM sodium phosphate, pH 7.5.

Centrifuge the vial prior to opening. Avoid freeze-thaw cycles.

Reconstitute in water to a concentration of 0.1-1.0 mg/mL. The solution can then be diluted into other aqueous buffers.